Abstract:BackgroundType 2 inflammation is common in numerous atopic/allergic diseases and can be identified by elevated biomarker levels. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key and central drivers of type 2 inflammation. ObjectiveAssessment of dupilumab effect on type 2 inflammatory biomarkers in atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and eosinophilic esophagitis (EoE). MethodsData were extracted from three randomized placebo-controlled trials of dupilumab in AD (NCT02277743, N=671; NCT02277769, N=708; NCT02260986, N=740); and one each in asthma (NCT02414854, N=1902); CRSwNP (NCT02898454, N=448); and EoE (NCT02379052, N=47). Biomarkers assessed were serum thymus and activation-regulated chemokine (TARC), plasma eotaxin-3, serum total immunoglobulin E (IgE), serum periostin, and blood eosinophil count. ResultsDupilumab versus placebo significantly suppressed most type 2 inflammatory biomarker levels across all studies/indications where data were assessed. Reductions in serum TARC, plasma eotaxin-3, and serum periostin occurred rapidly, whereas reductions in serum total IgE were more gradual. Across diseases, at the end of treatment, median percentage change from baseline in TARC levels ranged from −24.8% to −88.6% (placebo +2.6% to −53.6%); −38.2% to −51.5% (placebo +8.3% to −0.16%) in eotaxin-3; −24.8% to −76.7% (placebo +8.3% to −4.4%) in total IgE; and −13.6% to −41.1% (placebo +10.1% to −6.94%) in periostin levels. Blood eosinophil responses to dupilumab varied by disease, with minimal changes in AD in the SOLO studies (median percentage change from baseline to end of treatment: 0% [95% CI: −15.8, 0]); transient increases followed by decreases to below-baseline levels in asthma (−14.6% [−20.0, −7.7]) and CRSwNP (−29.4% [−40.0, −16.3]); and significant decreases in EoE (−50.0% [−50.0, −33.3]). Conclusion and clinical relevanceDupilumab reduced levels of type 2 biomarkers across clinical studies in patients with AD, asthma, CRSwNP, and EoE.

Potential Indications of Dupilumab in Th-2 Inflammatory Disease

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence

Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases

Dupilumab: Mechanism of action, clinical, and translational science

Global influence of dupilumab on Quality of Life in a severe asthma patient with T2 multimorbidities: a case report on atopic dermatitis, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis

Effects of dupilumab on hair in patients with atopic dermatitis - a review of the literature

Laboratory Safety of Dupilumab, and Its Effect on Inflammatory Biomarkers, in Chinese Adults with Moderate-to-Severe Atopic Dermatitis: an Analysis of a Randomized, Double-Blind Phase III Study

Severe pediatric asthma therapy: Dupilumab

Dupilumab in real-life settings: a review of adverse events and their pathogenesis

Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature

Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation

An Updated Reappraisal of Dupilumab in Children and Adolescents with Severe Asthma

Dupilumab treatment ameliorates clinical and hematological symptoms, including blood eosinophilia, in patients with atopic dermatitis

Use of dupilumab for recalcitrant bullous pemphigoid: A case report

Phase 2a randomized clinical trial of dupilumab (anti‐IL‐4Rα) for alopecia areata patients

Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells

Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials

Dupilumab as Therapeutic Option in Polysensitized Atopic Dermatitis Patients Suffering from Food Allergy

Dupilumab as a treatment for cutaneous immune-related adverse events induced by immune checkpoint inhibitors: A case series and review of the literature

Dupilumab for prurigo nodularis: Case series and review of the literature